Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 1,452 Shares of Company Stock

Key Points

• Nurix insider Gwenn Hansen sold 1,452 shares at $25.00 each for $36,300 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 1.22% to 117,227 shares.
• NRIX shares traded near $24.95, with a $2.59 billion market capitalization and a 52-week range of $9.71 to $28.23. The company reported quarterly earnings of $4.73 per share and revenue of $673.06 million, significantly exceeding analyst expectations.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $34.64; Nurix also initiated a Phase 3 trial of bexobrutideg for relapsed or refractory blood cancers.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 1,452 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.00, for a total value of $36,300.00. Following the completion of the transaction, the insider owned 117,227 shares in the company, valued at approximately $2,930,675. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total value of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded up $1.28 during midday trading on Thursday, hitting $24.95. The company's stock had a trading volume of 3,753,438 shares, compared to its average volume of 1,512,604. The business's fifty day simple moving average is $25.14 and its two-hundred day simple moving average is $21.06. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of 10.80 and a beta of 1.82. Nurix Therapeutics, Inc. has a 1 year low of $9.71 and a 1 year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%. The firm had revenue of $673.06 million for the quarter, compared to analyst estimates of $24.35 million. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Nurix Therapeutics by 95.4% in the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company's stock valued at $30,000 after purchasing an additional 620 shares during the period. Nykredit A S acquired a new stake in Nurix Therapeutics in the second quarter valued at about $32,000. Integrated Wealth Concepts LLC acquired a new position in Nurix Therapeutics during the 2nd quarter worth approximately $33,000. KBC Group NV acquired a new stake in shares of Nurix Therapeutics in the 1st quarter valued at approximately $34,000. Finally, Avalon Trust Co acquired a new position in Nurix Therapeutics during the second quarter worth $64,000.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst maintained a “Strong Buy” rating, citing promising earlier-stage data, potential accelerated approval and multiple development opportunities. Bexobrutideg clinical analysis
• Positive Sentiment: Analyst sentiment remains broadly bullish. Baird raised its price target to $36 and maintained an “Outperform” rating, while Needham reiterated “Buy” with a $34 target. The consensus target is approximately $34.64, above recent trading levels. Nurix analyst ratings
• Neutral Sentiment: Nurix’s quarterly results significantly exceeded estimates, with earnings of $4.73 per share versus a projected loss of $0.60 and revenue of $673.06 million versus a $24.35 million consensus estimate. However, the earnings reaction was tempered by higher operating expenses as the company continues investing in its pipeline. Nurix quarterly earnings
• Negative Sentiment: Truist reduced its price target for Nurix while retaining a “Buy” rating, signaling more cautious near-term expectations despite confidence in the company’s longer-term prospects. Truist price target update
• Negative Sentiment: Director Julia Gregory sold 22,583 shares for about $528,000, reducing her direct ownership by 67.75%. Separately, insider Gwenn Hansen sold 1,452 shares for $36,300 under a pre-arranged Rule 10b5-1 plan. While planned sales may reflect diversification or personal financial needs, the transactions can weigh on investor sentiment. Nurix insider sale filing

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NRIX shares. Robert W. Baird boosted their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an "outperform" rating in a research note on Tuesday. Stifel Nicolaus set a $41.00 price target on Nurix Therapeutics in a research note on Tuesday. Mizuho lifted their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Finally, UBS Group upped their price objective on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.64.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix's pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton's tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.